Delving into the Latest Updates on Trabectedin with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Ecteinascidin, ecteinascidin 743, Trabectedin (JAN/USAN/INN)

+ [6]

Target

DNA

Action

inhibitors, inducers

Mechanism

DNA inhibitors(DNA inhibitors), Apoptosis inducers, DNA alkylating agents

Therapeutic Areas

NeoplasmsEndocrinology and Metabolic DiseaseUrogenital Diseases+ [2]

Active Indication

LeiomyosarcomaSoft Tissue NeoplasmsLiposarcoma+ [11]

Inactive Indication

Advanced breast cancerAdvanced cancerAdvanced Liposarcoma+ [16]

Originator Organization

Active Organization

+ [5]

Inactive Organization

Johnson & Johnson Pharmaceutical Research & Development LLCJanssen-Cilag International NVJanssen Research & Development LLC

+ [4]

Drug Highest PhaseApproved

First Approval Date

European Union (17 Sep 2007),

Platinum-Sensitive Ovarian CarcinomaSarcoma

RegulationOrphan Drug (United States), Orphan Drug (South Korea), Orphan Drug (Australia), Orphan Drug (Japan)

Login to view timeline

Structure/Sequence

Molecular FormulaC39H43N3O11S

InChIKeyPKVRCIRHQMSYJX-AIFWHQITSA-N

CAS Registry114899-77-3

Chemotherapy with Trabectedin is an effective treatment for sarcoma patients in the second line setting or in first line for patients who are deemed unsuitable to receive anthracycline therapy. The prospective study will primarily investigate the PRO of Trabectedin rechallenge in patients with soft tissue sarcomas that had to discontinue initial Trabectedin treatment due to various reasons such as progression, side effects or surgery, as is commonly the case in real-life settings. Embedding this trial in the GISAR registry enables the evaluation of a large number of patients with long-term follow-up which allows multiple analyses regarding different questions that remain unanswered until today.

Start Date31 Oct 2023

Sponsor / Collaborator

Institut fr Klinische Krebsforschung IKF GmbH

[+1]

NCT04794127

/ RecruitingPhase 2IIT

A Phase II Study on Trabectedin in Combination With PPARg Agonist Pioglitazone in Patients With Round Cell Myxoid Liposarcomas or Dedifferentiated G1 and G2 Liposarcomas With Stable Disease After a Monotherapy With Trabectedin. (TRABEPIO)

This is a phase 2 study conducted in two sequential stages:
The first stage is an Italian single institution, single arm, pilot study, aimed at exploring the activity of the combination T and P in myxoid liposarcoma patients who achieved a stable disease after a minimum of 4 cycles of T alone. If a minimum required activity will be demonstrated from the first stage, the second stage of the study will be conducted;otherwise, the study will be stopped. The second stage is an Italian open-label, multicenter, randomized, double arm, phase II trial, aimed at evaluating the combination of T and P in myxoid liposarcoma and G1 or G2 dedifferentiated liposarcomas compared to the standard treatment with T alone. Patients will be randomized with a 1:1 ratio to treatments arms as specified below:
Control arm (A): T alone
Experimental arm (B): T in combination with P

Start Date02 Feb 2022

Sponsor / Collaborator

Fondazione Irccs Istituto Nazionale Dei Tumori

[+1]

100 Clinical Results associated with Trabectedin

Login to view more data

100 Translational Medicine associated with Trabectedin

Login to view more data

100 Patents (Medical) associated with Trabectedin

Login to view more data

1,445

Literatures (Medical) associated with Trabectedin

02 Apr 2025·Cancer Immunology Research

Trabectedin Enhances the Antitumor Effects of IL-12 in Triple-Negative Breast Cancer

Article

Author: Lapurga, Gabriella ; Carson, William E. ; Cripe, Timothy P. ; Ringwalt, Emily M. ; Savardekar, Himanshu ; Miller, Katherine E. ; Rivaldi, Adithe ; Lyberger, Justin ; Yu, Lianbo ; Behbehani, Gregory K. ; Schwarz, Emily ; Mouse, Abigail ; Zelinskas, Sara

Abstract:

IL-12 is a potent NK cell–stimulating cytokine, but the presence of immunosuppressive myeloid cells such as myeloid-derived suppressor cells (MDSC) can inhibit IL-12–induced NK-cell cytotoxicity. Thus, we hypothesized that trabectedin, a myeloid cell–depleting agent, would improve the efficacy of IL-12 in triple-negative breast cancer (TNBC). In vitro treatment of healthy donor NK cells with trabectedin increased expression of the activation marker CD69 and mRNA expression of T-box transcription factor (Tbx21), the cytotoxic ligands TNF-related apoptosis–inducing ligand (TNFSF10), Fas ligand (FASLG), and the dendritic cell (DC)–recruiting chemokine lymphotactin (XCL1). The combination of IL-12 and trabectedin increased NK-cell cytotoxicity and activation and production of IFN-γ, TNF-α, and granzyme B in the presence of human TNBC cells. Treatment of 4T1 and EMT6 tumor–bearing mice with IL-12 and trabectedin led to a significant reduction in tumor burden compared with single-agent controls and the highest levels of plasma IFN-γ, intratumoral CD8+ T cells, and conventional type 1 DC. MDSC and M2-like macrophages were significantly decreased with combination therapy. NK-cell depletion abrogated the effects of combination therapy, as did the elimination of CD8+ T cells. NK-cell depletion led to lower levels of the NK cell–derived chemokine CCL5 and the DC-derived chemokine CXCL10, higher tumor burden, and decreased intratumoral CD8+ T cells. IL-12 and trabectedin also significantly enhanced the response of TNBC to anti–PD-L1 therapy. These data suggest that MDSC depletion augments the ability of IL-12–activated NK cells to drive the infiltration of DC and CD8+ T cells into TNBC for an antitumor effect.

28 Mar 2025·Future Oncology

Doxorubicin and trabectedin in leiomyosarcoma: pioneering a new era of smart combinations in soft tissue sarcomas

Author: Assi, Tarek ; Le Cesne, Axel

01 Mar 2025·ANNALS OF SURGICAL ONCOLOGY

Sarcoma: Last Year’s Practice Changing Papers

Review

Author: van Houdt, Winan J ; Gronchi, Alessandro

BACKGROUND:

In 2023 and 2024, a wide variety of new studies have been published in the field of soft tissue sarcomas, representing the enormous heterogeneity of sarcoma histotypes, anatomical location, treatment variability, and biological behavior.

PATIENTS AND METHODS:

This article summarizes the, in our view, seven most important publications in the field that will have an impact on the surgical practice and future treatment strategies of our patients.

RESULTS:

In the last year, we gained more insight in the genetic background of patients with sarcoma from a large Australian study, which will have an impact on future counseling and screening of our patients. Also, the role of radiotherapy in retroperitoneal liposarcoma became clearer in the combined STRASS-STREXIT study. Radiotherapy for extremity sarcomas can now also be done in a 3-week, hypofractioned manner, which is a major improvement for our patients. Furthermore, more evidence has been presented regarding the improved outcome of patients with retroperitoneal sarcoma when treated in high volume centers. Landmark studies with systemic treatment include the positive trial with nirogacestat in desmoid tumors, which have finally shifted the paradigm of desmoid treatment from surgery to systemic treatment. Also, the results of 2 phase 3 randomized controlled trials recently showed 1) that the combination of doxorubicin with trabectedin significantly improved progression free survival for patients with leiomyosarcoma when compared with doxorubicin alone and 2) that the combination of neoadjuvant pembrolizumab and radiotherapy followed by 1-yr adjuvant pembrolizumab significantly improved disease free survival for patients with primary localized undifferentiated pleomorphic sarcoma/myxofibrosarcoma or dedifferentiated/pleomorphic liposarcoma of the extremities or girdles.

CONCLUSIONS:

Key papers from the last year informs us that management of soft tissues sarcoma is constantly improving, since more data became available to guide us in defining the best treatment strategies.

62

News (Medical) associated with Trabectedin

17 Apr 2025

·www.globenewswire.com

Moleculin Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025

HOUSTON, April 17, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viruses, today announced that an abstract regarding the Company’s next-generation anthracycline, Annamycin, has been selected for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025, taking place April 25-30, 2025, at the McCormick Place Convention Center in Chicago, IL. Details of the presentation are as follows: Title: Combining Annamycin, a Non-cardiotoxic Potent Topo II Poison, with Azacitidine, Cytarabine, Gemcitabine, Ifosfamide, Trabectedin, or Vincristine to Synergize Anticancer Effects and Identify Potential Clinical ApplicationsTrack: Experimental and Molecular TherapeuticsSession: PO.ET02.03. Drug Combination Strategies for Cancer TreatmentAbstract Number: 1683/ 14Presenter: Rafal Zielinski, Ph.D., Department of Experimental Therapeutics, Division of Cancer Medicine, MD Anderson Cancer CenterDate and Time: April 28, 2025, 9:00 AM – 12:00 PM ETLocation: Section 19For more information and to view the abstract, visit the AACR Annual Meeting website. About Moleculin Biotech, Inc. Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses. The Company’s lead program, Annamycin, is a next-generation anthracycline designed to avoid multidrug resistance mechanisms and to eliminate the cardiotoxicity common with currently prescribed anthracyclines. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.The Company is initiating the MIRACLE (Moleculin R/R AML AnnAraC Clinical Evaluation) Trial (MB-108), a pivotal, adaptive design Phase 3 trial evaluating Annamycin in combination with cytarabine, together referred to as AnnAraC, for the treatment of relapsed or refractory acute myeloid leukemia. Following a successful Phase 1B/2 study (MB-106), with input from the FDA, the Company believes it has substantially de-risked the development pathway towards a potential approval for Annamycin for the treatment of AML. This study is subject to appropriate future filings with potential additional feedback from the FDA and their foreign equivalents.Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers. Moleculin is also engaged in the development of a portfolio of antimetabolites, including WP1122 for the potential treatment of pathogenic viruses, as well as certain cancer indications. For more information about the Company, please visit www.moleculin.com and connect on X, LinkedIn and Facebook. Forward-Looking StatementsSome of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the timing of the achievements of each of the milestones in this press release. Moleculin will require significant additional financing, for which the Company has no commitments, in order to conduct its clinical trials as described in this press release, and the milestones described in this press release assume the Company’s ability to secure such financing on a timely basis. Although Moleculin believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Moleculin has attempted to identify forward-looking statements by terminology including ‘believes,’ ‘estimates,’ ‘anticipates,’ ‘expects,’ ‘plans,’ ‘projects,’ ‘intends,’ ‘potential,’ ‘may,’ ‘could,’ ‘might,’ ‘will,’ ‘should,’ ‘approximately’ or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. “Risk Factors” in our most recently filed Form 10-K filed with the Securities and Exchange Commission (SEC) and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events. Investor Contact:JTC Team, LLCJenene Thomas(908) 824-0775MBRX@jtcir.com

Phase 3AACR

28 Feb 2025

·www.fiercepharma.com

Eisai, Biogen's Leqembi emerges from safety reappraisal unscathed as Europe's CHMP endorses slate of new drugs and label expansions

For Eisai and Biogen, the European Medicines Agency’s Committee for Medicinal Products for Human Use’s decision to stick by its previous call on Leqembi now punts the final approval verdict back to the European Commission, which is the ultimate authority on whether a drug scores marketing authorization in the EU. Following a flurry of activity at this month’s meeting of the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), drugmakers are celebrating a bevy of endorsements for big-name meds.Over the course of the sit-down, which ran from Monday through Thursday, the CHMP recommended four new drugs for approval, teed up another 16 potential label expansions and—in a major win for Eisai and Biogen—reaffirmed the positive opinion on the Alzheimer’s disease drug Leqembi (lecanemab) it first issued in November, according to the agency’s meeting summary Friday.For Eisai and Biogen, the CHMP’s decision to stick by its previous call now punts the final approval verdict for Leqembi back to the European Commission (EC), which is the ultimate authority on whether a drug scores marketing authorization in the EU.Despite Leqembi winning the CHMP’s favor in November—albeit in a somewhat restricted patient population—the European regulator last month said it would honor the EC’s request to consider new safety data on the antibody that surfaced after the initial thumbs-up, Biogen explained in a Friday press release.“The safety profile of lecanemab reported in clinical practice in the United States, Japan and other countries after launch is consistent with that in the approved labels, and no new safety signals are identified,” Biogen said of the situation last month. The CHMP has specifically backed Leqembi to treat mild cognitive impairment or mild dementia from Alzheimer’s but only for patients carrying one or no copy of the ApoE4 gene. Patients with two copies of the gene are at greater risk of brain swelling or bleeding side effects known as amyloid-related imaging abnormalities, according to trial data. Elsewhere, the CHMP this week advanced four new drugs for potential European approvals. Those are: Takeda’s immunoglobulin drug Deqsiga, Regeneron’s multiple myeloma antibody Lynozyfic, Krystal Biotech’s dystrophic epidermolysis bullosa gene therapy Vyjuvek and Accord Healthcare’s generic drug trabectedin, which has been endorsed in advanced soft tissue sarcoma and relapsed platinum-sensitive ovarian cancer.As for proposed label expansions, the CHMP endorsed new uses for drugs from Vertex, Novartis, AbbVie, Eli Lilly and many other companies.In Lilly’s case, the regulator recommended approval for the company’s BTK inhibitor Jaypirca to treat adults with relapsed or refractory chronic lymphocytic leukemia (CLL) who’ve already tried another medication from the same class.In addition to the new positive opinion in CLL, the drug also boasts a conditional European nod in mantle cell lymphoma, Lilly noted in a press release.AbbVie, for its part, got the CHMP’s backing in its bid to expand Rinvoq’s reach into the inflammatory disease giant cell arteritis, while Novartis’ Fabhalta received the agency’s blessing to treat adults with C3 glomerulopathy (C3G). C3G is an ultrarare kidney disease—often striking when people are young—that currently lacks any approved treatment options, Novartis said Friday.Other major label expansions that passed muster with the CHMP include those for Vertex’s Kaftrio and Kalydeco in combination to treat cystic fibrosis patients 2 and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator gene, plus a bid to expand the use of Valneva’s chikungunya vaccine Ixchiq to provide active immunization for kids starting at age 12. Notably, several drugmakers withdrew applications from the CHMP.Sanofi, for example, pulled the plug on efforts to score a European label expansion for Dupixent to treat moderate to severe chronic spontaneous urticaria in adults and adolescents, according to the committee's update. Plus, Spanish biotech HIPRA withdrew the application for an adapted version of its COVID-19 vaccine Bimervax targeting an updated strain of the SARS-CoV-2 virus.

Drug ApprovalVaccine

28 Feb 2025

·endpts.com

CHMP recommends Regeneron, Novartis drugs that still await FDA approval

The European Medicines Agency’s human medicines committee (CHMP) has recommended four new drugs for approval, including Regeneron’s Lynozyfic for the treatment of relapsed and refractory multiple myeloma. The recommendation is a step forward for Regeneron in Europe after the FDA last August rejected its drug in the US over manufacturing issues . The FDA has set a new decision deadline of July 10. CHMP also suggested that the European Commission approve Krystal Biotech’s Vyjuvek for the treatment of wounds in patients with dystrophic epidermolysis bullosa, a genetic skin condition. The other recommendations were for Accord Healthcare’s generic trabectedin and Takeda’s immunoglobulin drug Deqsiga. The European Commission has the final authority over new drug approvals, but it typically follows CHMP’s recommendations. CHMP also recommended 16 label expansions, including Novartis’ Fabhalta for the treatment of rare kidney disease C3 glomerulopathy (C3G), which currently has no approved medicines. Fabhalta is currently approved by the EMA as a treatment for hemolytic anemia in patients with a blood disease called paroxysmal nocturnal hemoglobinuria. The FDA is reviewing Fabhalta for C3G, with a decision date expected by June . The agency was supposed to hold a meeting for the kidney drug this week but it was canceled for unknown reasons . CHMP said that no changes need to be made to Eisai and Biogen’s Alzheimer’s drug Leqembi, after the commission had requested a review of the drug’s market authorization in January. A review was requested after CHMP gave a positive opinion on the drug to treat Alzheimer’s patients with only one or no copy of the ApoE4 gene in November 2024. CHMP had previously rejected Leqembi in July 2024. CHMP’s other label expansion recommendations include:

Drug ApprovalAccelerated Approval

100 Deals associated with Trabectedin

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D06199	Trabectedin	L01CX01	DB05109

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Leiomyosarcoma	United States	Janssen Products LP	23 Oct 2015
Soft Tissue Neoplasms	Japan	Taiho Pharmaceutical Co., Ltd.	28 Sep 2015
Liposarcoma	Canada	Valeo Pharma, Inc.	05 Aug 2010
Soft Tissue Sarcoma	South Korea	Verto Korea	22 Apr 2008
Platinum-Sensitive Ovarian Carcinoma	European Union	Pharma Mar SA	17 Sep 2007
Platinum-Sensitive Ovarian Carcinoma	Iceland	Pharma Mar SA	17 Sep 2007
Platinum-Sensitive Ovarian Carcinoma	Liechtenstein	Pharma Mar SA	17 Sep 2007
Platinum-Sensitive Ovarian Carcinoma	Norway	Pharma Mar SA	17 Sep 2007
Sarcoma	European Union	Pharma Mar SA	17 Sep 2007
Sarcoma	Iceland	Pharma Mar SA	17 Sep 2007
Sarcoma	Liechtenstein	Pharma Mar SA	17 Sep 2007
Sarcoma	Norway	Pharma Mar SA	17 Sep 2007

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Synovial Sarcoma	Phase 3	Italy	Pharma Mar SA	28 Feb 2019
Metastatic Soft Tissue Sarcoma	Phase 3	France	Pharma Mar SA	07 Nov 2017
Metastatic Soft Tissue Sarcoma	Phase 3	Germany	Pharma Mar SA	07 Nov 2017
Metastatic Soft Tissue Sarcoma	Phase 3	Netherlands	Pharma Mar SA	07 Nov 2017
Metastatic Soft Tissue Sarcoma	Phase 3	Poland	Pharma Mar SA	07 Nov 2017
Metastatic Soft Tissue Sarcoma	Phase 3	Spain	Pharma Mar SA	07 Nov 2017
Metastatic Soft Tissue Sarcoma	Phase 3	United Kingdom	Pharma Mar SA	07 Nov 2017
Platinum-Sensitive Fallopian Tube Carcinoma	Phase 3	United States	Pharma Mar SA	16 Oct 2013
Platinum-Sensitive Fallopian Tube Carcinoma	Phase 3	United States	Janssen Research & Development LLC	16 Oct 2013
Platinum-Sensitive Fallopian Tube Carcinoma	Phase 3	China	Pharma Mar SA	16 Oct 2013

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ESMO_SRC2025	Not Applicable	Soft Tissue Sarcoma Cytochrome P450 (CYP 3A4)	51	Trabectedin	vyzalcqzea(livysppaav) = acljjlmljs qptikqtzzw (zfpowjjgdy )	Positive	21 Mar 2025
ESMO_SRC2025	Not Applicable	Langerhans Cell Sarcoma	332	Trabectedin RDI<80%	qkmsvydmoj(xnfnwpkree) = mdjavimrla xifcpgkzhu (nclukflhrc ) View more	Negative	21 Mar 2025
				Trabectedin RDI≥80%	qkmsvydmoj(xnfnwpkree) = vwnlybbvyn xifcpgkzhu (nclukflhrc ) View more
NCT03164980 (COMPASS, CTgov)	Phase 4	Platinum-Sensitive Primary Peritoneal Carcinoma \| Platinum-Sensitive Ovarian Carcinoma \| Recurrent ovarian cancer ... View more	89	Trabectidin (Yondelis) (Arm A)	rlxcuzyptp(cnlcxikenr) = aoottkpxga qberoaoqtw (gtlkusjfnb, 15.6) View more	-	20 Mar 2025
				Trabectidin (Yondelis) (Arm B)	rlxcuzyptp(cnlcxikenr) = prxltbjsvb qberoaoqtw (gtlkusjfnb, 14.7) View more
709 (SITC2024)	Not Applicable	Malignant glioma of brain	9	Trabectedin	ffjqmwiqzd(adtynkywep) = skueltowrd smujwcsefr (gmyftoqzpv )	Positive	05 Nov 2024
				Anti-PD1 immunotherapy	ffjqmwiqzd(adtynkywep) = xvgpycbogs smujwcsefr (gmyftoqzpv )
NCT03127215 (AIO-STS \| TF-0117 \| ass, ESMO2024) Manual	Phase 2	Solid tumor DNA repair deficiencies	117	Trabectedin olaparib (TrO)TrO)	ogypxjlaob(dvariyzlid) = uklldjogsd rlcrbtqupm (ljgkmxvusp ) View more	Negative	15 Sep 2024
				Physician’s choice (PC)	ogypxjlaob(dvariyzlid) = cnahxfwtcu rlcrbtqupm (ljgkmxvusp )
NCT03138161 (SAINT, ESMO2024) Manual	Phase 2	Soft Tissue Sarcoma First line	97	TrabectedinIpilimumabnivolumab	hxocayvwbi(suypxoudkx) = wwvtwgocou gmqqmdxcyu (qichemlyuk, 5.247 - 9.353) View more	Positive	14 Sep 2024
ESMO2024	Not Applicable	Soft Tissue Sarcoma Second line \| Third line	207	Trabectedin	hstoshaliq(phgbwgkhey) = qnnfmsfsgn rfxwdxutjn (ntzsiuwrpe ) View more	Positive	14 Sep 2024
				Trabectedin + Radiotherapy	hstoshaliq(phgbwgkhey) = plxducacei rfxwdxutjn (ntzsiuwrpe ) View more
NCT02997358 (LMS04, Pubmed \| N Engl J Med) Manual	Phase 3	Leiomyosarcoma Maintenance \| First line	150	Doxorubicin+Trabectedin	khwdiygbbr(dnsbtcypxe) = pqbgofnyki kdzhhawtxj (pdzzkwfjfr, 10 - 16) View more	Positive	05 Sep 2024
				Doxorubicin	khwdiygbbr(dnsbtcypxe) = ygdnsdwajm kdzhhawtxj (pdzzkwfjfr, 4 - 7) View more
NCT04076579 (CTgov)	Phase 2	Metastatic osteosarcoma	29	Olaparib+Trabectedin (Cohort 1)	gxryhimida = gpogknkvmx akkjrwlrnp (bslounfqym, goweognsmt - dzqxivnppc) View more	-	29 Jul 2024
				Olaparib+Trabectedin (Cohort 2)	gxryhimida = gkrxnavhpv akkjrwlrnp (bslounfqym, hkbrzrdnyr - ziqbmmlafh) View more
NCT04067115 (SARC037, ASCO2024) Manual	Phase 2	Recurrent Ewing Sarcoma \| Refractory Ewing Sarcoma	16	Trabectedin 1 irinotecan	jcgctqpins(uonxfdbokx) = gvjarkrkov fjzxdojkrq (yndlkuraev, 18.3 - 77.7) View more	Positive	24 May 2024